Liquid Biopsy in Type 2 Diabetes Mellitus Management: Building Specific Biosignatures via Machine Learning.

Makrina KaraglaniMaria PanagopoulouChristina Cheimonidi Ioannis TsamardinosEfstratios MaltezosNikoloas PapanasDimitrios PapazoglouMastorakos George Ekaterini Chatzaki

Published in: Journal of clinical medicine (2022)

Our data unravel the value of ccfDNA as a minimally invasive biomaterial carrying important clinical information for T2DM. Upon prospective clinical evaluation, the built biosignature can be disruptive for T2DM clinical management.

Keyphrases

clinical evaluation
minimally invasive
machine learning
big data
electronic health record
artificial intelligence
glycemic control
ultrasound guided
ionic liquid
fine needle aspiration
health information
robot assisted
healthcare
data analysis